Evaluation of gadobenate dimeglumine in hepatocellular carcinoma: Results from phase II and phase III clinical trials in Japan

Journal of Magnetic Resonance Imaging

Volumn 10, Issue 3, 1999, Pages 450-460

  Tanimoto, Akihiro ^a   Kuwatsuru, Ryohei ^b   Kadoya, Masumi ^c   Ohtomo, Kuni ^d   Hirohashi, Shinji ^e   Murakami, Takamichi ^f   Hiramatsu, Kyoichi ^a   Yoshikawa, Kohki ^g   Katayama, Hitoshi ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e NARA MEDICAL UNIVERSITY   (Japan)

^f OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

Author keywords

Contrast media; Gadolinium; Gd BOPTA; Gd DTPA; Hepatocellular carcinoma; Liver; Magnetic resonance imaging

Indexed keywords

CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG INDUCED DISEASE; DRUG SAFETY; EPIGASTRIC PAIN; HUMAN; IMAGE ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SIGNAL NOISE RATIO;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INJECTIONS, INTRAVENOUS; JAPAN; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MEGLUMINE; MIDDLE AGED; MULTICENTER STUDIES; ORGANOMETALLIC COMPOUNDS;

EID: 0032825639     PISSN: 10531807     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1522-2586(199909)10:3<450::AID-JMRI29>3.0.CO;2-K     Document Type: Article

References (23)

1. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809.
2. Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Safety, tolerability, biodistribution and MR enhancement of the liver with Gd-BOPTA: results of clinical pharmacology and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-291.
3. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins. Invest Radiol 1997;32:780-796.
4. Spinazzi A, Lorusso V, Pirovano G, et al. MultiHance clinical pharmacology: biodistribution and MR enhancement of the liver. Acad Radiol 1998;5(suppl 1):S86-S89.
5. Vogl TJ, Pegios W, McMahon C, et al. Gadobenate dimeglumine - a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR 1992;157:887-892.
6. Caudana R, Morana G, Pirovano G, et al. Focal malignant hepatic lesions: MR imaging enhanced with gadolinium benzyloxypropionic-tetra-acetate (BOPTA) - preliminary results of phase II clinical application. Radiology 1996;199:513-520.
7. Petersein J, Pirovano G, Spinazzi A, et al. Evaluation of the efficacy of gadobenate dimeglumine in MR imaging of focal liver lesions: a multicenter phase III clinical study (ms. in preparation).
8. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Clinical late phase II trials of MultiHance (Gd-BOPTA) for the MR imaging of liver tumors in Japan. J Comput Assist Tomogr in press.
9. Mirowitz SA, Lee JKT, Gutierrez E, et al. Dynamic gadolinium-enhanced rapid acquisition spin-echo MR imaging of the liver. Radiology 1991;179:371-376.
10. Hamm B, Thoeni RF, Gould RG, et al. Focal liver lesions: characterization with nonenhanced and dynamic contrast material-enhanced MR imaging. Radiology 1994;190:417-423.
11. Kuwatsuru R, Kadoya M, Ohtomo K, et al. Clinical late phase III trials of MultiHance (Gd-BOPTA) for the MR imaging of liver tumors in Japan: comparison with Magnevist (ms. in preparation).
12. Cavagna F, Tirone P, Felder E, de Haën C. Hepatobiliary contrast agents for MRI. In: Ferrucci JT, Stark DD, eds. Liver imaging. Boston: Andover Medical Publishers; 1990. p 384-393.
13. Vittadini G, Felder E, Tirone P, Lorusso V. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol 1988;23:S246-S248.
14. Schumann-Gianpieri G. Liver contrast media for magnetic resonance imaging: interrelations between pharmacokinetics and imaging. Invest Radiol 1993;28:753-761.
15. Vogl TJ, Kummel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200:59-67.
16. Oi H, Murakami T, Kim T, et al. Dynamic MR imaging and early-phase helical CT for detecting small intrahepatic metastases of hepatocellular carcinoma. AJR 1996;166:369-374.
17. Hamm B, Mahfouz A, Taupitz M, et al. Liver metastases: improved detection with dynamic gadolinium-enhanced MR imaging? Radiology 1997;202:677-682.
18. Vogl TJ, Stupavsky A, Pegios W, et al. Hepatocellular carcinoma: evaluation with dynamic and static gadobenate dimeglumine-enhanced MR imaging and histopathologic correlation. Radiology 1997;205:721-728.
19. Manfredi R, Maresca G, Baron RL, et al. Gadobenate dimeglumine (BOPTA)-enhanced MR imaging: patterns of enhancement in normal liver and cirrhosis. J Magn Reson Imaging 1998;8:862-867.
20. Ni Y, Marchal G, Yu J, et al. Prolonged positive enhancement with Gd-EOB-DTPA in experimental liver tumors: potential value in tissue characterization. J Magn Reson Imaging 1994;4:355-363.
21. Terada T, Kadoya M, Nakanuma Y, Matsui O. Iron-accumulating adenomatous hyperplastic nodule with malignant foci in the cirrhotic liver. Histopathologic, quantitative iron, and magnetic resonance imaging in vitro studies. Cancer 1990;65:1994-2000.
22. Mitchell DG, Stolpen AH, Siegelman ES, Bolinger L, Outwater EK. Fatty tissue on opposed-phase MR images: paradoxical suppression of signal intensity by paramagnetic contrast agents. Radiology 1996;198:351-357.
23. Kadoya M, Kawamori Y, Matsui O, et al. Paradoxical signal suppression of focal fatty lesion in opposed-phase GRE dynamic MR imaging: a pitfall in the differential diagnosis of hepatic neoplasm. In: 8th Asian & Oceanian Congress of Radiology, Kobe, Book of Abstracts, 249, April 1998.